News

Raludotatug deruxtecan has been granted Breakthrough Therapy Designation (BTD) by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with platinum-resistant epithelial ovarian, primary peritoneal or fallopian tube cancers expressing CDH6 who have received prior treatment with bevacizumab.

Charles River Laboratories International, Inc. has recently announced two strategic collaborations across its contract development and manufacturing organization (CDMO), aimed at advancing novel

The pharmaceutical industry is implementing cutting-edge cleanroom technologies to enhance manufacturing efficiency and compliance.

A leading biotechnology firm announces a $75 million funding round to expand its contract research organization services.

Scipher Medicine, a pioneer in network-based and AI-driven precision immunology, today announced a strategic collaboration with Maxymune Therapeutics, a biotechnology company focused on research

A leading biotech firm has acquired a revolutionary gene editing technology to streamline drug development processes.

Lawmakers have introduced a bill designed to expedite clinical trial processes by enhancing regulatory frameworks.

Major players in the pharmaceutical industry have formed a coalition to enhance drug manufacturing technologies and reduce production costs.

A newly proposed regulatory framework aims to expedite the approval process for innovative biotech products.

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation